Friday , September 21 2018
Home / Resources / Articles / Albiglutide Effective as Part of Triple Therapy in T2DM

Albiglutide Effective as Part of Triple Therapy in T2DM

Jan 16, 2015

The GLP-1 agonist albiglutide was added to the regimen of patients already on metformin and glimepiride…

How helpful was this article? (Please vote.)

An international team of researchers investigated the efficacy and tolerability of albiglutide, a weekly glucagon-like peptide-1 receptor (GLP-1) agonist, when added to metformin and glimepiride in a triple therapy regimen in people with type 2 diabetes mellitus.

This was a 156-week, randomized, double-blind, parallel-group, multicenter study. Adult participants (n = 685) were randomly assigned to albiglutide (30 mg/week), pioglitazone (30 mg/day) or placebo. If needed, blinded uptitration of albiglutide (to 50 mg/week) and pioglitazone (to 45 mg/day) was allowed. The participant’s current dose of metformin (>1500 mg/day) was maintained throughout. The glimepiride dose (4 mg/day), standardized before randomization, could be decreased if persistent hypoglycemia occurred.

The week 52 model-adjusted difference in change of glycated hemoglobin (primary endpoint) for albiglutide versus placebo was -0.87 [95% confidence interval (CI) -1.07, -0.68]%-units (p < 0.001), and for albiglutide versus pioglitazone it was 0.25 (95% CI 0.10, 0.40)%-units; therefore, not non-inferior. In the albiglutide group only, fasting plasma glucose reduced rapidly in the first 2 weeks. Confirmed hypoglycemia occurred in 14% of participants on albiglutide, 25% on pioglitazone and 14% on placebo. The mean (± standard error) weight change was -0.42 (±0.2) kg with albiglutide, +4.4 (±0.2) kg (p < 0.001) with pioglitazone, and -0.40 (±0.4) kg with placebo and serious adverse events occurred in 6.3, 9.0 and 6.1% of participants in the respective groups. Injection site reactions occurred in 13% of participants on albiglutide and resulted in treatment discontinuation for four participants (1.4%).

The researchers concluded that albiglutide as part of triple therapy provided effective glucose-lowering and was generally well-tolerated.

Practice Pearls:

  • In this double-blind, randomized study, researchers followed 685 adults taking metformin and glimepiride at baseline. Albiglutide, pioglitazone, or placebo was added to their regimen. After 1 year, the model-adjusted difference in HbA1c for albiglutide vs placebo was −0.87 (P < .001). In the albiglutide group only, fasting plasma glucose reduced rapidly in the first 2 weeks. Confirmed hypoglycemia occurred in 14% with albiglutide, 25% with pioglitazone, and 14% with placebo.
  • As a part of triple therapy, albiglutide was effective and well-tolerated.

Efficacy and Tolerability of Albiglutide Versus Placebo or Pioglitazone Over 1 Year in People With Type 2 Diabetes Currently Taking Metformin and Glimepiride: HARMONY 5 Diabetes Obes Metab 2014 Dec 10;[EPub Ahead of Print], PD Home